Bpifrance’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bpifrance’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,418	Closed	-$218K	–	7
2020 Q2	$218K	Buy	+12,418	New	+$212K	0.05%	7

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bpifrance's CRNX Position: Q3 2020 in Review

Bpifrance sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2020, closing a stake of 12,418 shares — an estimated $218K sold.

Bpifrance first reported a position in CRNX in Q2 2020 and held it in 1 quarter. The position peaked at $218K in Q2 2020. 71 funds tracked by Wall St. Rank hold CRNX as of Q3 2020.

Bpifrance reported no remaining Crinetics Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bpifrance sold 12,418 Crinetics Pharmaceuticals shares in Q3 2020, an estimated $218K.
Bpifrance first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Bpifrance's Crinetics Pharmaceuticals position peaked at $218K in Q2 2020.
71 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2020.

Based on Bpifrance's 13F filing for Q3 2020, filed 3 Nov 2020.